Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·1d ago
More News
New Strong Sell Stocks for August 6th
ACIU, ABEV and ALX have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2025.
Zacks·2mo ago
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of -25.00% and -57.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.
read more...
Benzinga·11mo ago
Gold Down Over 1%; AC Immune Shares Spike Higher
read more...
Benzinga·1y ago
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
read more...
Benzinga·1y ago
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimers Disease
Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immunes active immunotherapies targeting toxic forms of amyloid...
Business Wire·1y ago
Futures Gain With All Time Highs In Sight As Key CPI Report Looms
Futures Gain With All Time Highs In Sight As Key CPI Report Looms
US equity futures extended last week's solid gains when they traded just about 1% below all time highs, as investors...